Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eSCOUT: Cetuximab, Irinotecan, Oxaliplatin and UFT in First Line Metastatic Colorectal Cancer
NCT01225744Phase 2Completed
- Sponsor
- The Christie
- Start
- Apr 2009
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, tegafur + uracil in colorectal cancer (CRC), sponsored by The Christie. Started Apr 2009; status: completed.
02
Drugs
KL-140irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatintegafur + uracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01225744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01225744.